Sanofi chose Hanmi against threat of Lantus patent expiration

The reason why Sanofi established a technology transfer contract worth of KRW 5 trillion with Hanmi Pharm is analyzed as the company considered the patent expiration of ‘Lantus,’ its largest insulin product.

Lantus, a daily injection, is the most well-known product of Sanofi, which records KRW 9 trillion annual sales. However, the company is about to face biosimilar competition from patent exp...